Photo taken from Amol Akhade/Twitter
Oct 21, 2023, 19:37
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil’s Suyog Cancer Clinics, Thane, shared on X/Twitter an insight from ESMO23:
“Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO. We have better questions to answer. Like IO resistance. Let’s use our resources better.”
Source: Amol Akhade/Twitter.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 26, 2025, 13:55
Aug 26, 2025, 13:50
Aug 26, 2025, 13:42
Aug 26, 2025, 13:36
Aug 26, 2025, 13:16